On Tuesday, Pacira BioSciences, Inc. (NASDAQ:PCRX) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is a ...

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system ...

BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...

In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...

SPARTANBURG — Evelyn Gilliam knows the dangers of opioids from her job as a substance abuse counselor at the Forrester Center for Behavioral Health. So she was happy to hear there was a drug-free ...

Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).

-- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE ...

TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported ...

The separate reimbursement for iovera° will pay up to an additional $255.85 when providers administer iovera° in ASC and HOPD settings, using a new C-code created for the iovera° system (C9809). This ...

TAMPA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported ...